Autolus Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor events in March 2026. The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2028 at 11:10am EST / 4:10pm GMT, with CEO Dr. Christian Itin presenting and a webcast available. A replay will be archived for 90 days. Management will host investor meetings at Jefferies Biotech on the Beach Summit on March 10, 2026 in Miami, FL.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
On the day this news was published, AUTL gained 5.20%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.9% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $25M to the company's valuation, bringing the market cap to $514M at that time.
Data tracked by StockTitan Argus on the day of publication.
LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.
TD Cowen 46th Annual Health Care Conference
Date and time: March 3, 2028; 11:10am EST / 4:10pm GMT
Location: Boston, MA
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 10, 2026
Location: Miami, FL
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com